ID   PC-14
AC   CVCL_1640
SY   PC 14; PC14
DR   BTO; BTO:0002877
DR   CLO; CLO_0008394
DR   EFO; EFO_0002844
DR   CLDB; cl3880
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 388
DR   BioSample; SAMN10987800
DR   cancercelllines; CVCL_1640
DR   Cell_Model_Passport; SIDM00237
DR   CGH-DB; 205-1
DR   CGH-DB; 9169-4
DR   ChEMBL-Cells; CHEMBL3307306
DR   ChEMBL-Targets; CHEMBL614140
DR   Cosmic; 753608
DR   Cosmic; 801577
DR   Cosmic; 876138
DR   Cosmic; 897744
DR   Cosmic; 932924
DR   Cosmic; 946060
DR   Cosmic; 1239897
DR   Cosmic; 1571737
DR   Cosmic; 1656894
DR   Cosmic; 1995612
DR   Cosmic; 2125282
DR   Cosmic; 2668308
DR   Cosmic-CLP; 753608
DR   DepMap; ACH-000030
DR   ECACC; 90071810
DR   EGA; EGAS00001000978
DR   GDSC; 753608
DR   GEO; GSM827410
DR   GEO; GSM887505
DR   GEO; GSM888587
DR   GEO; GSM1670338
DR   IARC_TP53; 11872
DR   IARC_TP53; 21133
DR   LiGeA; CCLE_627
DR   LINCS_LDP; LCL-1656
DR   PharmacoDB; PC14_1247_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1640
DR   PubChem_Cell_line; CVCL_1640
DR   RCB; RCB0446
DR   Wikidata; Q54938396
RX   PubMed=1847845;
RX   PubMed=4094096;
RX   PubMed=10358721;
RX   PubMed=10536175;
RX   PubMed=11005564;
RX   PubMed=11416159;
RX   PubMed=14581340;
RX   PubMed=15185009;
RX   PubMed=15746151;
RX   PubMed=15901131;
RX   PubMed=16105816;
RX   PubMed=19472407;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20557307;
RX   PubMed=22313637;
RX   PubMed=22460905;
RX   PubMed=25120651;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://cell.brc.riken.jp/en/rcb/rcb0446_announce
CC   Problematic cell line: Contaminated. Shown to be a PC-9 derivative (RCB=RCB0446).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   From: Immuno-Biological Laboratories (IBL); Tokyo; Japan.
CC   Population: Japanese.
CC   HLA typing: A*02:06,24:02; B*39:01,55:01; C*03:03,07:02; DQB1*05:01,06:02; DRB1*01:01,15:05 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (PubMed=16105816).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=15901131; Cosmic-CLP).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.88%; Native American=0%; East Asian, North=83.17%; East Asian, South=13.42%; South Asian=0.81%; European, North=0%; European, South=1.72% (PubMed=30894373).
CC   Caution: TP53 mutation indicated incorrectly as being at c.742C>T in PubMed=10536175 and PubMed=20557307.
CC   Discontinued: RCB; RCB0446; true.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): Cosmic-CLP; ECACC; PubMed=11416159
ST   Amelogenin: X
ST   CSF1PO: 11
ST   D13S317: 8
ST   D16S539: 9
ST   D18S51: 15
ST   D21S11: 29,30
ST   D5S818: 11
ST   D7S820: 10 (ECACC)
ST   D7S820: 10,11 (Cosmic-CLP)
ST   D8S1179: 11,15
ST   FGA: 23,25
ST   TH01: 7
ST   TPOX: 11
ST   vWA: 17
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B260 ! PC-9
SX   Male
AG   45Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 41
//
RX   PubMed=1847845; DOI=10.1007/BF00685110;
RA   Sasaki Y., Shinkai T., Eguchi K., Tamura T., Ohe Y., Ohmori T.,
RA   Saijo N.;
RT   "Prediction of the antitumor activity of new platinum analogs based on
RT   their ex vivo pharmacodynamics as determined by bioassay.";
RL   Cancer Chemother. Pharmacol. 27:263-270(1991).
//
RX   PubMed=4094096; DOI=10.1093/oxfordjournals.jjco.a039097;
RA   Lee Y.-C., Saijo N., Sasaki Y., Takahashi H., Sakurai M., Ishihara J.,
RA   Hoshi A., Chen K.-M., Hamburger A.W.;
RT   "Clonogenic patterns of human pulmonary adenocarcinoma cell lines (PC-9,
RT   PC-13 and PC-14) and how they influence the results of test for
RT   chemosensitivity to cisplatin in the human tumor clonogenic assay.";
RL   Jpn. J. Clin. Oncol. 15:637-644(1985).
//
RX   PubMed=10358721; DOI=10.18926/AMO/31626;
RA   Matsushita A., Tabata M., Ueoka H., Kiura K., Shibayama T., Aoe K.,
RA   Kohara H., Harada M.;
RT   "Establishment of a drug sensitivity panel using human lung cancer
RT   cell lines.";
RL   Acta Med. Okayama 53:67-75(1999).
//
RX   PubMed=10536175; DOI=10.3892/ijo.15.5.927;
RA   Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.;
RT   "Comprehensive analysis of p53 gene mutation characteristics in lung
RT   carcinoma with special reference to histological subtypes.";
RL   Int. J. Oncol. 15:927-934(1999).
//
RX   PubMed=11005564; DOI=10.1038/sj.neo.7900094;
RA   Kohno T., Sato T., Takakura S., Takei K., Inoue K., Nishioka M.,
RA   Yokota J.;
RT   "Mutation and expression of the DCC gene in human lung cancer.";
RL   Neoplasia 2:300-305(2000).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=14581340;
RA   Yokoi S., Yasui K., Iizasa T., Imoto I., Fujisawa T., Inazawa J.;
RT   "TERC identified as a probable target within the 3q26 amplicon that is
RT   detected frequently in non-small cell lung cancers.";
RL   Clin. Cancer Res. 9:4705-4713(2003).
//
RX   PubMed=15185009; DOI=10.1007/s00262-004-0533-9;
RA   Yamaji H., Iizasa T., Koh E., Suzuki M., Otsuji M., Chang H.,
RA   Motohashi S., Yokoi S., Hiroshima K., Tagawa M., Nakayama T.,
RA   Fujisawa T.;
RT   "Correlation between interleukin 6 production and tumor proliferation
RT   in non-small cell lung cancer.";
RL   Cancer Immunol. Immunother. 53:786-792(2004).
//
RX   PubMed=15746151; DOI=10.1093/hmg/ddi092;
RA   Izumi H., Inoue J., Yokoi S., Hosoda H., Shibata T., Sunamori M.,
RA   Hirohashi S., Inazawa J., Imoto I.;
RT   "Frequent silencing of DBC1 is by genetic or epigenetic mechanisms in
RT   non-small cell lung cancers.";
RL   Hum. Mol. Genet. 14:997-1007(2005).
//
RX   PubMed=15901131; DOI=10.1016/j.prp.2005.01.002;
RA   Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.;
RT   "Correlation between DNA alterations and p53 and p16 protein
RT   expression in cancer cell lines.";
RL   Pathol. Res. Pract. 201:109-115(2005).
//
RX   PubMed=16105816; DOI=10.1158/0008-5472.CAN-05-0331;
RA   Nagai Y., Miyazawa H., Huqun X., Tanaka T., Udagawa K., Kato M.,
RA   Fukuyama S., Yokote A., Kobayashi K., Kanazawa M., Hagiwara K.;
RT   "Genetic heterogeneity of the epidermal growth factor receptor in
RT   non-small cell lung cancer cell lines revealed by a rapid and
RT   sensitive detection system, the peptide nucleic acid-locked nucleic
RT   acid PCR clamp.";
RL   Cancer Res. 65:7276-7282(2005).
//
RX   PubMed=19472407; DOI=10.1002/humu.21028;
RA   Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R.,
RA   Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.;
RT   "A gene-alteration profile of human lung cancer cell lines.";
RL   Hum. Mutat. 30:1199-1206(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x;
RA   Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.;
RT   "Prevalence of human papillomavirus 16/18/33 infection and p53
RT   mutation in lung adenocarcinoma.";
RL   Cancer Sci. 101:1891-1896(2010).
//
RX   PubMed=22313637; DOI=10.4161/cbt.19238;
RA   Takata M., Chikumi H., Miyake N., Adachi K., Kanamori Y., Yamasaki A.,
RA   Igishi T., Burioka N., Nanba E., Shimizu E.;
RT   "Lack of AKT activation in lung cancer cells with EGFR mutation is a
RT   novel marker of cetuximab sensitivity.";
RL   Cancer Biol. Ther. 13:369-378(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25120651; DOI=10.3892/ol.2014.2234;
RA   Suzuki M., Ikeda K., Shiraishi K., Eguchi A., Mori T., Yoshimoto K.,
RA   Shibata H., Ito T., Baba Y., Baba H.;
RT   "Aberrant methylation and silencing of IRF8 expression in non-small
RT   cell lung cancer.";
RL   Oncol. Lett. 8:1025-1030(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//